Work

A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.347

Authors: Ritesh Kotecha, Chung-Han Lee, Deaglan Joseph McHugh, Chloe Dadoun, Andrea Knezevic, Maria Isabel Carlo, Emily Feld, Natalie Shapnik, Neil J. Shah, Darren R. Feldman, Robert J. Motzer, Martin H Voss

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4213049706

Cites:

Cited by: 2

Related to: 10